Tuesday, February 02, 2021 3:44:29 PM
$VXRT THEN 1. Oral formulations vs Liquid inoculations
[remember $KIN has partnered wit $VXRT]
https://www.fool.com/investing/2020/08/13/3-reasons-doctors-will-prefer-vaxarts-coronavirus/
1. Oral formulations make for easier storage and transport
When most people think of vaccines, they think of a syringe filled with liquid which is administered by a healthcare worker into the muscles or veins of the patient.
In contrast, Vaxart's technology platform produces oral tablets containing the equivalent active components.
This may seem like a minor distinction,
but it's actually a critical factor that works strongly to Vaxart's advantage when it comes to currying favor with doctors and other providers.
Liquid inoculations typically require refrigeration during manufacturing, shipping, and storage at the point of use.
If they aren't consistently kept at the correct temperature, their efficacy may drop, or they may spoil completely.
This means that traditional liquid vaccines imply a substantial logistical burden on healthcare systems,
as well as their suppliers, as a result of the additional refrigeration hardware and energy expenditures required.
Vaxart's tablets are stable at room temperature, however,
so healthcare systems won't need to spend nearly as much to transport or store its coronavirus prophylactic,
and the risk of spoilage is much low
2. Tablets don't require any consumables to administer
When patients get an inoculation in tablet form, there's no need
for the clinic that distributed it to purchase additional disposable syringes, sterilizing swabs, bandages, or even gloves.
As a bonus, after the patient has taken the vaccine, clinics won't
need to pay for additional biohazard trash removal services to dispose of the used materials.
Thanks to the sum of these savings, healthcare systems won't need to spend as much to administer Vaxart's candidate as they might with a traditional liquid inoculation,
enabling them to vaccinate more patients than they could otherwise.
If these savings seem like they might be trivial, consider that an effective coronavirus prophylactic program would need to be deployed
to about 3 billion people globally,
which could easily create shortages and price spikes for the basic healthcare materials or services required for traditional liquid vaccinations.
3. Less risky self-administration
You've probably taken pills without a doctor or nurse standing at
your side to supervise,
but it's unlikely that you've ever prepared and self-injected a vaccination on your own.
With an oral tablet, Vaxart hopes that patients will have the freedom
to vaccinate themselves in the safety of their homes.
This would be particularly advantageous because it would nullify the risk of patients getting infected in crowded clinics while waiting for their turn to be inoculated.
Vaxart's inoculations win via superior logistics, but oral vaccines aren't for everyone
Vaxart's shelf-stable, syringe-free, and easy-to-deploy prophylactic tablets would thus be popular among clinicians around the world thanks to their lower costs,
and savvy investors should recognize that these advantages could be decisive for future earnings.
However, there is one reason why doctors in underdeveloped regions might not favor Vaxart's candidate.
While the scientific consensus is still forming,
it may be the case that malnutrition makes oral vaccination less effective compared with intramuscular vaccination, especially in children.
Therefore, clinics in areas with low food security might opt for a traditional formulation instead of Vaxart's solution.
Even with this potential disadvantage, I think that the vaccine's logistical strengths -- should it be approved
-- will give the company an enduring advantage over the competition.
Time will tell whether Vaxart's coronavirus candidate can live up
to the necessary medical standards. In the meantime, look for the company's phase 1 clinical trial to start later in the summer.
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
The Motley Fool has a disclosure policy.
Recent VXRT News
- Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 12:00:13 PM
- Vaxart Provides Business Update and Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:01:00 PM
- U.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices Climb • IH Market News • 03/14/2024 11:41:01 AM
- Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:23:54 PM
- Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:10:21 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:16:04 PM
- Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge • GlobeNewswire Inc. • 02/05/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/02/2024 09:49:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 10:14:20 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/19/2024 09:30:58 PM
- Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate • GlobeNewswire Inc. • 01/19/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 10:18:45 PM
- Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management • GlobeNewswire Inc. • 01/16/2024 02:25:20 PM
- Vaxart, Inc. Announces Management Change • GlobeNewswire Inc. • 01/16/2024 02:22:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 02:19:43 PM
- Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers • GlobeNewswire Inc. • 12/21/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:16:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 08:11:19 PM
- Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/02/2023 08:01:22 PM
- Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2 • GlobeNewswire Inc. • 10/26/2023 12:00:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM